Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -4.10%90 Days Payable is 134.96 as of Jun. 2026, which is 49% above its 10-year median of 90.29. GuruFocus rates NSE:BETA with a GF Score™ of 90/100 and a GF Value™ of ₹2,684.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Beta Drugs ranks better than 73.3% on this metric.
Beta Drugs's average Accounts Payable for the
three
months ended in Jun. 2026 was ₹806 Mil. Beta Drugs's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹545 Mil.
Hence, Beta Drugs's Days Payable for the
three
months ended in Jun. 2026 was 134.96.
The historical rank and industry rank for Beta Drugs's Days Payable or its related term are showing as below:
NSE:BETA'
s Days Payable Range Over the Past 10 Years
Min: 54.79 Med: 90.29 Max: 161.92
Current: 144.73
During the past 13 years, Beta Drugs's highest Days Payable was 161.92. The lowest was 54.79. And the median was 90.29.
NSE:BETA's Days Payable is ranked better than 73.3% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.27
vs NSE:BETA: 144.73
Beta Drugs's Days Payable
increased
from Jun. 2025 (130.70) to Jun. 2026 (134.96).
It may suggest that Beta Drugsdelayed paying its suppliers.
The historical data trend for Beta Drugs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Days Payable distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Beta Drugs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Days Payable of 134.96 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beta Drugs and its competitors. This is 49% above median its historical median of 90.29. Over the past decade, Beta Drugs' Days Payable has ranged from 54.79 to 161.92. According to the industry distribution chart, Beta Drugs ranks #247 out of 925 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Beta Drugs' Days Payable too high?
Beta Drugs' current Days Payable of 134.96 is 49% above median its 10-year median of 90.29. Over the past 10 years, this metric has ranged from a low of 54.79 to a high of 161.92. The Drug Manufacturers industry median Days Payable is 89.27. Beta Drugs' value of 134.96 is 51.2% above this industry median. Based on the distribution chart, Beta Drugs ranks #247 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #247 out of 925 companies for Days Payable. This puts Beta Drugs in the upper half of its industry. The industry median Days Payable is 89.27. Beta Drugs' value of 134.96 is 51.2% above this benchmark. Historically, Beta Drugs' own Days Payable has ranged from 54.79 to 161.92 over the past decade. While the company's 10-year median is 90.29 vs. the industry median of 89.27, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.27, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Days Payable of 134.96 is 51.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Days Payable is 134.96, which is 49% above median its own 10-year median of 90.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,684.50, compared to a current price of ₹2,559.00 — trading 4.7% below its estimated fair value. The current Days Payable is 134.96, which is 49% above median its 10-year median of 90.29 and 51.2% above the Drug Manufacturers industry median of 89.27. Beta Drugs' overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Days Payable is 134.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,559.00 is trading 4.7% below its estimated GF Value™ of ₹2,684.50.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Days Payable: 134.96 (49% above median its 10-year median of 90.29)
GF Value™: ₹2,684.50 vs. price of ₹2,559.00 (4.7% below fair value)
Industry Position: 51.2% above the Drug Manufacturers median (#247 of 925)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score
Get the complete analysis for NSE:BETA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
